Overall, these studies provide insight into how CCL2 and HGF function to coordinate breast cancer growth, survival, invasion, and metabolism, and demonstrate that targeting CCR2 and MET inhibit DCIS progression. This evidence concerns the gene CCR2 and breast carcinoma.